Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 1/2016

01-01-2016 | Review

The continuing evolution of targeted therapy for inflammatory skin disease

Authors: C. Schlapbach, A. A. Navarini

Published in: Seminars in Immunopathology | Issue 1/2016

Login to get access

Abstract

Treatment of inflammatory skin disease has evolved from non-specific suppression of immune cells to increasingly precise targeting and modulation of immune mechanisms at all levels. This has led to dramatic treatment successes and deepened understanding of the pathophysiology. The cycle of in vitro studies, animal models, clinical trials, and case series of non-primary indications is a feedback loop that informs and guides the design of ever better disease models and therapeutic targets. Not only are we constantly discovering new molecules driving skin inflammation, we have also found that psoriasis and other autoimmune conditions are driven by distinct mediators occurring in early and late phases, which could be an opportunity for phase-specific or multipronged interventions. The deeper our mechanistic understanding, the more likely we will be able to discover subtle strategies to reprogram each patients’ immune cells without having to dampen or eliminate their protective effects against pathogens and tumors. Lastly, ongoing genomic studies might soon confirm interesting genetic markers for predictive personalized medicine, the earliest currently being evaluated in psoriasis such as HLA-Cw6 and TNFAIP3. Taken together, the continued evolution of immune therapies in skin will potentially allow an unprecedented form of medicine that is not bent on silencing the pathogenic mechanism, but rather aims at using subtle interventions to shepherd the immune cell swarm back on the correct path.
Literature
1.
Noda S, Krueger JG, Guttman-Yassky E (2015) The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 135:324–336PubMedCrossRef
2.
3.
4.
Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450–456PubMedCrossRef
5.
van Kempen TS, Wenink MH, Leijten EF, Radstake TR, Boes M. Perception of self: distinguishing autoimmunity from autoinflammation. Nat Rev Rheumatol 2015
6.
Christophers E, Metzler G, Rocken M (2014) Bimodal immune activation in psoriasis. Br J Dermatol 170:59–65PubMedCrossRef
7.
Kakeda M, Schlapbach C, Danelon G et al (2014) Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Arch Dermatol Res 306:933–938PubMedCrossRef
8.
Nestle FO, Conrad C, Tun-Kyi A et al (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202:135–143PubMedPubMedCentralCrossRef
9.
Schubert C, Christophers E (1985) Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res 277:352–358PubMedCrossRef
10.
Biedermann T, Kneilling M, Mailhammer R et al (2000) Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 192:1441–1452PubMedPubMedCentralCrossRef
11.
Tamagawa-Mineoka R, Okuzawa Y, Masuda K, Katoh N (2014) Increased serum levels of interleukin 33 in patients with atopic dermatitis. J Am Acad Dermatol 70:882–888PubMedCrossRef
12.
Kim BS, Siracusa MC, Saenz SA et al (2013) TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 5:170ra16PubMedPubMedCentralCrossRef
13.
Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H (2009) IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 123:1047–1054PubMedPubMedCentralCrossRef
14.
Maier E, Werner D, Duschl A, Bohle B, Horejs-Hoeck J (2014) Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-kappaB-dependent way. J Immunol (Baltimore, Md : 1950) 193:645–654CrossRef
15.
16.
Eichenfield LF, Tom WL, Chamlin SL et al (2014) Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol 70:338–351PubMedPubMedCentralCrossRef
17.
Harden JL, Johnson-Huang LM, Chamian MF et al (2015) Humanized anti-IFN-gamma (HuZAF) in the treatment of psoriasis. J Allergy Clin Immunol 135:553–556PubMedCrossRef
18.
Guttman-Yassky E, Lowes MA, Fuentes-Duculan J et al (2007) Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol 119:1210–1217PubMedCrossRef
19.
20.
Johnson-Huang LM, Suarez-Farinas M, Pierson KC et al (2012) A single intradermal injection of IFN-gamma induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol 132:1177–1187PubMedPubMedCentralCrossRef
21.
Conrad C, Boyman O, Tonel G et al (2007) Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 13:836–842PubMedCrossRef
22.
Perera GK, Ainali C, Semenova E et al (2014) Integrative biology approach identifies cytokine targeting strategies for psoriasis. Sci Transl Med 6:223ra22PubMedCrossRef
23.
Taylor PR, Roy S, Leal SM Jr et al (2014) Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORgammat and dectin-2. Nat Immunol 15:143–151PubMedPubMedCentralCrossRef
24.
Guttman-Yassky E, Nograles KE, Krueger JG (2011) Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol 127:1420–1432PubMedCrossRef
25.
Mansouri B, Richards L, Menter A (2014) Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab. Br J Dermatol
26.
27.
Prat L, Bouaziz JD, Wallach D, Vignon-Pennamen MD, Bagot M (2014) Neutrophilic dermatoses as systemic diseases. Clin Dermatol 32:376–388PubMedCrossRef
28.
Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8:942–949PubMedCrossRef
29.
Oldhoff JM, Darsow U, Werfel T et al (2006) No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 141:290–294PubMedCrossRef
30.
Oldhoff JM, Darsow U, Werfel T et al (2005) Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60:693–696PubMedCrossRef
31.
Hamilton JD, Suarez-Farinas M, Dhingra N et al (2014) Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 134:1293–1300PubMedCrossRef
32.
Beck LA, Thaci D, Hamilton JD et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130–139PubMedCrossRef
33.
Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU (2008) Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 121:122–128PubMedCrossRef
34.
Navarini AA, French LE, Hofbauer GF (2011) Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 128:1128–1130PubMedCrossRef
35.
Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448–457PubMedCrossRef
36.
Schmitt E, Klein M, Bopp T (2014) Th9 cells, new players in adaptive immunity. Trends Immunol 35:61–68PubMedCrossRef
37.
Licona-Limon P, Henao-Mejia J, Temann AU et al (2013) Th9 cells drive host immunity against gastrointestinal worm infection. Immunity 39:744–757PubMedCrossRef
38.
Schlapbach C, Gehad A, Yang C et al (2014) Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci Transl Med 6:219ra8PubMedPubMedCentralCrossRef
39.
Turner JE, Morrison PJ, Wilhelm C et al (2013) IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med 210:2951–2965PubMedPubMedCentralCrossRef
40.
Wilhelm C, Hirota K, Stieglitz B et al (2011) An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 12:1071–1077PubMedPubMedCentralCrossRef
41.
Oh CK, Leigh R, McLaurin KK, Kim K, Hultquist M, Molfino NA (2013) A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res 14:93PubMedPubMedCentralCrossRef
42.
Ghoreschi K, Thomas P, Breit S et al (2003) Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 9:40–46PubMedCrossRef
43.
Reich K, Garbe C, Blaschke V et al (2001) Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 116:319–329PubMedCrossRef
44.
Trepicchio WL, Ozawa M, Walters IB et al (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104:1527–1537PubMedPubMedCentralCrossRef
45.
Guenova E, Skabytska Y, Hoetzenecker W et al (2015) IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci U S A 112:2163–2168PubMedPubMedCentralCrossRef
46.
Lammermann T, Afonso PV, Angermann BR et al (2013) Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature 498:371–375PubMedCrossRef
47.
48.
Eyerich S, Onken AT, Weidinger S et al (2011) Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 365:231–238PubMedCrossRef
49.
Kroemer G, Galluzzi L (2015) Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—an exclamation sign with a question mark. Oncoimmunology 4:e1058037PubMedCrossRef
50.
Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133PubMedCrossRef
51.
Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M et al (2011) Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131:677–687PubMedCrossRef
52.
Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH (2009) Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31:331–341PubMedCrossRef
53.
Thaci D, Ortonne JP, Chimenti S et al (2010) A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 163:402–411PubMedCrossRef
54.
Tsapas A, Matthews DR (2009) Using N-of-1 trials in evidence-based clinical practice. JAMA 301:1022–1023, author reply 3 PubMedCrossRef
55.
Clark RA, Watanabe R, Teague JE et al (2012) Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 4:117ra7PubMedPubMedCentralCrossRef
56.
Hernandez MV, Nogues S, Ruiz-Esquide V, Alsina M, Canete JD, Sanmarti R (2009) Development of alopecia areata after biological therapy with TNF-alpha blockers: description of a case and review of the literature. Clin Exp Rheumatol 27:892–893PubMed
57.
Tauber M, Beneton N, Reygagne P, Bachelez H, Viguier M (2013) Alopecia areata developing during ustekinumab therapy: report of two cases. Eur J Dermatol : EJD 23:912–913PubMed
58.
Price VH, Hordinsky MK, Olsen EA et al (2008) Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol 58:395–402PubMedCrossRef
59.
Strober BE, Menon K, McMichael A et al (2009) Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. Arch Dermatol 145:1262–1266PubMedCrossRef
60.
Wright RC (2003) Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 49:160–161PubMedCrossRef
61.
Samorano LP, Hanifin JM, Simpson EL, Leshem YA (2014) Inadequate response to ustekinumab in atopic dermatitis—a report of two patients. J Eur Acad Dermatol Venereol : JEADV
62.
Fernandez-Anton Martinez MC, Alfageme Roldan F, Ciudad Blanco C, Suarez FR (2014) Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr 105:312–313PubMedCrossRef
63.
Sanchez-Ramon S, Eguiluz-Gracia I, Rodriguez-Mazariego ME et al (2013) Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 23:190–196PubMed
64.
Ibler K, Dam TN, Gniadecki R, Kragballe K, Jemec GB, Agner T (2010) Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. J Eur Acad Dermatol Venereol : JEADV 24:837–839PubMedCrossRef
65.
Moul DK, Routhouska SB, Robinson MR, Korman NJ (2008) Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 58:984–989PubMedCrossRef
66.
Cantarini L, Lopalco G, Caso F et al (2015) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet’s disease. Autoimmun Rev 14:1–9PubMedCrossRef
67.
Addimanda O, Pipitone N, Pazzola G, Salvarani C (2015) Tocilizumab for severe refractory neuro-Behcet: three cases IL-6 blockade in neuro-Behcet. Semin Arthritis Rheum 44:472–475PubMedCrossRef
68.
Vallet H, Riviere S, Sanna A et al (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behcet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74PubMedCrossRef
69.
Baerveldt EM, Kappen JH, Thio HB, van Laar JA, van Hagen PM, Prens EP (2013) Successful long-term triple disease control by ustekinumab in a patient with Behcet’s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis 72:626–627PubMedCrossRef
70.
Davatchi F, Shams H, Rezaipoor M et al (2010) Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13:246–252PubMedCrossRef
71.
Ricci M, Zauli S, Zelante A, Trevisani L, Virgili A, Bettoli V (2014) Bullous pemphigoid occurring under anti-tumor necrosis factor-alpha therapy. Int J Color Dis 29:1573–1574CrossRef
72.
Nakayama C, Fujita Y, Watanabe M, Shimizu H (2015) Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab. J Dermatol
73.
Majima Y, Yagi H, Tateishi C et al (2013) A successful treatment with ustekinumab in a case of antilaminin-gamma1 pemphigoid associated with psoriasis. Br J Dermatol 168:1367–1369PubMedCrossRef
74.
Cho YT, Chu CY, Wang LF (2015) First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol 173:302–304PubMedCrossRef
75.
Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT (2014) Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol 71:468–474PubMedCrossRef
76.
Monnier-Murina K, Du Thanh A, Merlet-Albran S, Guillot B, Dereure O (2009) Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical auto-immune reaction? Dermatology (Basel, Switzerland) 219:89–90CrossRef
77.
Kondo M, Murakawa Y, Matsumura T et al (2014) A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford) 53:1907–1908CrossRef
78.
Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47:877–880CrossRef
79.
Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324PubMedPubMedCentralCrossRef
80.
Huber A, Gaffal E, Bieber T, Tuting T, Wenzel J (2006) Treatment of recalcitrant dermatomyositis with efalizumab. Acta Derm Venereol 86:254–255PubMedCrossRef
81.
Navarini AA, Trueb RM (2010) 3 cases of dissecting cellulitis of the scalp treated with adalimumab: control of inflammation within residual structural disease. Arch Dermatol 146:517–520PubMed
82.
Amy de la Breteque M, Saussine A, Rybojad M, et al.(2014) Infliximab in recalcitrant granuloma annulare. Int J Dermatol
83.
Murdaca G, Colombo BM, Barabino G, Caiti M, Cagnati P, Puppo F (2010) Anti-tumor necrosis factor-alpha treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 11:437–439PubMedCrossRef
84.
Shah BK, Hewett Y, Peterson A, Tretheway D (2014) Resolution of granuloma annulare following treatment with bendamustine and rituximab in a patient with follicular lymphoma: a serendipitous finding. J Postgrad Med 60:406–408PubMedCrossRef
85.
Goffe BS (2004) Disseminated granuloma annulare resolved with the T-cell modulator efalizumab. Arch Dermatol 140:1287–1288PubMedCrossRef
86.
Hellwig Y, Yoo YE, Ress ML, et al. (2015) Fulminant skin GvHD with a cytokine pattern resemblant of cytokine release syndrome successfully treated with multimodal immunosuppression including tocilizumab. Pediatr Blood Cancer
87.
Kennedy GA, Varelias A, Vuckovic S et al (2014) Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 15:1451–1459PubMedCrossRef
88.
Couriel DR, Saliba R, de Lima M et al (2009) A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15:1555–1562PubMedPubMedCentralCrossRef
89.
Shapira MY, Resnick IB, Bitan M et al (2005) Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant 36:1097–1101PubMedCrossRef
90.
Hurd DS, Johnston C, Bevins A (2008) A case report of Hailey-Hailey disease treated with alefacept (Amevive). Br J Dermatol 158:399–401PubMed
91.
Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD (2014) An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 70:243–251PubMedCrossRef
92.
Martin-Ezquerra G, Masferrer E, Masferrer-Niubo M et al (2015) Use of biological treatments in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol : JEADV 29:56–60PubMedCrossRef
93.
Strober BE, Kim C, Siu K (2007) Efalizumab for the treatment of refractory hidradenitis suppurativa. J Am Acad Dermatol 57:1090–1091PubMedCrossRef
94.
Cohen PR, Kurzrock R (2014) Anakinra-responsive lichen planus in a woman with Erdheim-Chester disease: a therapeutic enigma. Dermatol Online J 20:21241PubMed
95.
Asarch A, Gottlieb AB, Lee J et al (2009) Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 61:104–111PubMedCrossRef
96.
Heelan K, McAleer MA, Roche L, McCreary C, Murphy M (2015) Intractable erosive lichen planus treated successfully with rituximab. Br J Dermatol 172:538–540PubMedCrossRef
97.
Seeborg FO, Rihal PS, Czelusta A, Sanchez R, Hanson IC (2009) Lichen planus associated with omalizumab administration in an adult with allergic asthma. Ann Allergy Asthma Immunol 102:349–351PubMedCrossRef
98.
Heffernan MP, Smith DI, Bentley D, Tabacchi M, Graves JE (2007) A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus. J Drugs Dermatol : JDD 6:310–314PubMed
99.
Moosig F, Zeuner R, Renk C, Schroder JO (2004) IL-1RA in refractory systemic lupus erythematosus. Lupus 13:605–606PubMedCrossRef
100.
Makol A, Gibson LE, Michet CJ (2012) Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol 18:92–95PubMedCrossRef
101.
Subramanian S, Yajnik V, Sands BE, Cullen G, Korzenik JR (2011) Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 17:99–104PubMedCrossRef
102.
De Souza A, Ali-Shaw T, Strober BE, Franks AG Jr (2011) Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol 147:896–898PubMedCrossRef
103.
Navarini AA, Kerl K, French LE, Trueb RM (2010) Control of widespread hypertrophic lupus erythematosus with T-cell-directed biologic efalizumab. Dermatology (Basel, Switzerland) 220:249–253CrossRef
104.
Berthelot C, Nash J, Duvic M (2007) Coexistent psoriasis and lupus erythematosus treated with alefacept. Am J Clin Dermatol 8:47–50PubMedCrossRef
105.
Hertl MS, Haendle I, Schuler G, Hertl M (2005) Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab. Br J Dermatol 152:552–555PubMedCrossRef
106.
Caso F, Iaccarino L, Bettio S et al (2013) Refractory pemphigus foliaceus and Behcet’s disease successfully treated with tocilizumab. Immunol Res 56:390–397PubMedCrossRef
107.
Jacobi A, Shuler G, Hertl M (2005) Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 153:448–449PubMedCrossRef
108.
Hall RP 3rd, Fairley J, Woodley D et al (2015) A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol 172:760–768PubMedCrossRef
109.
Kanwar AJ, Vinay K, Sawatkar GU et al (2014) Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol 170:1341–1349PubMedCrossRef
110.
Santos-Juanes J, Coto-Segura P, Saavedra J, Laviano S, Galache C (2009) Development of familial benign chronic pemphigus in a patient undergoing treatment with efalizumab for psoriasis. J Eur Acad Dermatol Venereol : JEADV 23:605–606PubMedCrossRef
111.
Adnot-Desanlis L, Antonicelli F, Tabary T, Bernard P, Reguiai Z (2013) Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition. Dermatology (Basel, Switzerland) 226:41–46CrossRef
112.
Wohlrab J, Kreft B (2010) Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol 163:655–656PubMedCrossRef
113.
Klein A, Szeimies RM, Landthaler M, Karrer S (2007) Exacerbation of pityriasis rubra pilaris under efalizumab therapy. Dermatology (Basel, Switzerland) 215:72–75CrossRef
114.
Gomez M, Ruelas ME, Welsh O, Arcaute HD, Ocampo-Candiani J (2007) Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient. J Drugs Dermatol : JDD 6:337–339PubMed
115.
Shima Y, Kuwahara Y, Murota H et al (2010) The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 49:2408–2412CrossRef
116.
Elhai M, Meunier M, Matucci-Cerinic M et al (2013) Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 72:1217–1220PubMedCrossRef
117.
Phumethum V, Jamal S, Johnson SR (2011) Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 38:289–296PubMedCrossRef
118.
Jordan S, Distler JH, Maurer B et al (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74:1188–1194PubMedCrossRef
119.
Chi GC, Hsu FS, Yang CC, Wei JC (2005) Scleroderma and failed response to alefacept. Rheumatology (Oxford) 44:1328–1330CrossRef
120.
Gonzalez-Lopez MA, Martinez-Taboada VM, Gonzalez-Vela MC, Fernandez-Llaca H, Val-Bernal JF (2008) New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra. Br J Dermatol 158:1146–1148PubMedCrossRef
121.
Palmou-Fontana N, Sanchez Gavino JA, McGonagle D, Garcia-Martinez E, Iniguezde Onzono Martin L (2014) Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology (Basel, Switzerland) 228:311–313CrossRef
122.
Reich K, Nestle FO, Papp K et al (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (London, England) 366:1367–1374CrossRef
123.
Papp KA, Langley RG, Lebwohl M et al (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet (London, England) 371:1675–1684CrossRef
124.
Langley RG, Elewski BE, Lebwohl M et al (2014) Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371:326–338PubMedCrossRef
125.
Toussirot E (2013) New onset of psoriasis in a patient with rheumatoid arthritis treated with rituximab. J Rheumatol 40:1230–1231PubMedCrossRef
126.
Pariser DM, Gordon KB, Papp KA et al (2005) Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled phase III trials: part I. J Cutan Med Surg 9:303–312PubMedCrossRef
127.
Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248–255PubMedCrossRef
128.
Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P (2009) Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 161:1199–1201PubMedCrossRef
129.
Acquitter M, Plantin P, Kupfer I, Auvinet H, Marhadour T (2015) Anakinra improves pyoderma gangrenosum in psoriatic arthritis: a case report. Ann Intern Med 163:70–71PubMedCrossRef
130.
Brooklyn TN, Dunnill MG, Shetty A et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55:505–509PubMedPubMedCentralCrossRef
131.
Guenova E, Teske A, Fehrenbacher B et al (2011) Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol 147:1203–1205PubMedCrossRef
132.
Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ (2011) Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat 22:261–265PubMedCrossRef
133.
Selva-Nayagam P, Fischer G, Hamann I, Sobel J, James C (2015) Rituximab causing deep ulcerative suppurative vaginitis/pyoderma gangrenosum. Curr Infect Dis Rep 17:478PubMedCrossRef
134.
Foss CE, Clark AR, Inabinet R, Camacho F, Jorizzo JL (2008) An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol : JEADV 22:943–949PubMedCrossRef
135.
Nutz A, Pernet C, Combe B, Cohen JD (2013) Sarcoidosis induced by tocilizumab: a paradoxical event? J Rheumatol 40:1773–1774PubMedCrossRef
136.
Rossman MD, Newman LS, Baughman RP et al (2006) A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 23:201–208PubMed
137.
Kaiser CA, Cozzio A, Hofbauer GF, Kamarashev J, French LE, Navarini AA (2011) Disfiguring annular sarcoidosis improved by adalimumab. Case Rep Dermatology 3:103–106CrossRef
138.
Judson MA, Baughman RP, Costabel U et al (2014) Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 44:1296–1307PubMedCrossRef
139.
140.
Garcia-Zuazaga J, Korman NJ (2006) Cutaneous sarcoidosis successfully treated with alefacept. J Cutan Med Surg 10:300–303PubMedCrossRef
141.
Devauchelle-Pensec V, Mariette X, Jousse-Joulin S et al (2014) Treatment of primary Sjogren syndrome with rituximab: a randomized trial. Ann Intern Med 160:233–242PubMedCrossRef
142.
Moutsopoulos NM, Katsifis GE, Angelov N et al (2008) Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis 67:1437–1443PubMedCrossRef
143.
Voigtlander C, Luftl M, Schuler G, Hertl M (2001) Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 137:1571–1574PubMedCrossRef
144.
Sauder MB, Glassman SJ (2013) Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis. Int J Dermatol 52:624–628PubMedCrossRef
145.
Kluger N, Gil-Bistes D, Guillot B, Bessis D (2011) Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret(R)) in a case of refractory Sweet’s syndrome. Dermatology (Basel, Switzerland) 222:123–127CrossRef
146.
Foster EN, Nguyen KK, Sheikh RA, Prindiville TP (2005) Crohn’s disease associated with Sweet’s syndrome and Sjogren’s syndrome treated with infliximab. Clin Dev Immunol 12:145–149PubMedPubMedCentralCrossRef
147.
Zarate-Correa LC, Carrillo-Gomez DC, Ramirez-Escobar AF, Serrano-Reyes C (2013) Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol 23:61–63PubMed
148.
Lowndes S, Darby A, Mead G, Lister A (2002) Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 13:1948–1950PubMedCrossRef
149.
(2005) Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 352:351–61
150.
Miloslavsky EM, Specks U, Merkel PA et al (2013) Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 65:2441–2449PubMedCrossRef
Metadata
Title
The continuing evolution of targeted therapy for inflammatory skin disease
Authors
C. Schlapbach
A. A. Navarini
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 1/2016
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-015-0524-2

Other articles of this Issue 1/2016

Seminars in Immunopathology 1/2016 Go to the issue

Review

Neutrophilic dermatoses and autoinflammatory diseases with skin involvement—innate immune disorders

Review

Update on psoriasis immunopathogenesis and targeted immunotherapy

Review

Cutaneous immunology: basics and new concepts

Review

Immune response in pemphigus and beyond: progresses and emerging concepts

Review

Lupus erythematosus revisited

Review

The role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatments
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits